Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of MGTX is 28 and suggests 271% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell